Omidenepag Isopropyl Versus Latanoprost in Primary Open-Angle Glaucoma and Ocular Hypertension: The Phase 3 AYAME Study

Aihara M., Lu F., Kawata H., Iwata A., Odani-Kawabata N., Shams N.K.

2020
American Journal of Ophthalmology

Therapeutic Area

Glaucoma
Categories

Clinical development

Affiliations

Department of Ophthalmology, University of Tokyo, Bunkyo-ku, Tokyo, Japan; Santen Inc., Emeryville, CA, United States; Santen Pharmaceutical Co. Ltd., Osaka, Japan

Related Publications

Metabolomic Profiling of Open-Angle Glaucoma Etiologic Endotypes: Tohoku Multi-Omics Glaucoma Study

Hanyuda A.; Raita Y.; Ninomiya T.; Hashimoto K.; Takada N.; Sato K.; Inoue J.; Koshiba S.; Tamiya G.; Narita A.; Akiyama M.; Omodaka K.; Tsuda S.; Yokoyama Y.; Himori N.; Yamamoto Y.; Taniguchi T.; Negishi K.; Nakazawa T.

Ocular Tissue Distribution of Omidenepag Isopropyl in Rabbits and Cynomolgus Monkeys

Yamamura K.; Mano H.; Fuwa M.; Ryoiwamura; Odani-Kawabata N.

Omidenepag Isopropyl 0.002% versus Latanoprost 0.005% in Open-Angle Glaucoma/Ocular Hypertension: The Randomized Phase III PEONY Trial

Wang T.H.; Aung T.; Lu D.-W.; George R.; Senthil S.; Lu F.; Odani-Kawabata N.; Park K.H.

View all Glaucoma publications